KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $674.6 million.

  • Sarepta Therapeutics' Net Cash Flow rose 153.84% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $412.8 million, marking a year-over-year increase of 218.73%. This contributed to the annual value of $674.6 million for FY2024, which is 224.51% up from last year.
  • According to the latest figures from FY2024, Sarepta Therapeutics' Net Cash Flow is $674.6 million, which was up 224.51% from -$541.8 million recorded in FY2023.
  • Sarepta Therapeutics' Net Cash Flow's 5-year high stood at $674.6 million during FY2024, with a 5-year trough of -$1.1 billion in FY2022.
  • In the last 3 years, Sarepta Therapeutics' Net Cash Flow had a median value of -$541.8 million in 2023 and averaged -$335.6 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Net Cash Flow tumbled by 285.68% in 2022 and then surged by 224.51% in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Net Cash Flow (Yearly) stood at $668.1 million in 2020, then fell by 8.12% to $613.8 million in 2021, then tumbled by 285.68% to -$1.1 billion in 2022, then soared by 52.46% to -$541.8 million in 2023, then skyrocketed by 224.51% to $674.6 million in 2024.